SLC1A5 and prostate cancer: Unlike 18F-fluorodeoxyglucose, it is not absorbed by all cells with an increased glucose metabolic rate, but specifically targets cell surface amino acid transporters ASCT2 and LAT1 overexpressed in prostate cancer.